Skip to content

Clinical benefits and considerations of dextromethorphan and bupropion administered separately for managing depression: A case report.

Parna Haghparast, Busuyi Olotu, Carol Yuan

Mental Health Clinician February 1, 2026 DOI: 10.9740/mhc.2026.02.030 (opens in new tab)

Study at a glance

AI-extracted from the abstract
Characteristics Case report Peer reviewed
Sample size 1
Population 31-year-old male with treatment-resistant depression and alcohol use disorder
Interventions bupropion dextromethorphan
Topics Depression
Keywords Bupropion Cost Dextromethorphan Over the counter
Key findings A 31-year-old man with treatment-resistant depression and alcohol use disorder experienced symptom improvement on bupropion and dextromethorphan.

Abstract

MDD can affect anyone regardless of age, and it often starts during late teens or early adulthood. Although some patients with MDD have an adequate response to medications, only approximately 50% respond to the first treatment, and approximately 30% do not achieve remission despite multiple interventions. Several strategies exist for treating patients who have failed multiple first-line agents, including switching to first-generation antidepressants or to antidepressants unavailable in generic. Other options include augmenting the current antidepressant with other medications such as antipsychotics. Alternatively, augmentation with electroconvulsive therapy, transcranial magnetic stimulation, or esketamine nasal spray can be considered. Prescribing antidepressants unavailable in generic limits accessibility to patients due to cost and prior authorization process. Dextromethorphan/bupropion, a new combination therapy, has shown promise in the treatment of MDD with efficacy seen as early as week 1. Although commercially available, cost and insurance limitations may necessitate consideration of separate administration of its components. This case report describes a 31-year-old male with a history of treatment-resistant depression and alcohol use disorder who experienced symptom improvement on bupropion and dextromethorphan. This case shares observations and clinical considerations of using such combinations in the management of treatment-resistant depression in the context of substance use disorder.

Comparable studies

Other case reports and case series on depression, most cited first.

Study Year Design Participants
Electroconvulsive Therapy, Ketamine, and Esketamine in a Patient with Major Depressive Disorder and Multiple Comorbidities: A Case Report over 10-year Treatment from Adolescence to Adulthood. A patient with treatment-resistant depression and comorbid generalized anxiety... 2025 Case report n = 1
Oral Administration of the NMDA Receptor Antagonist S-Ketamine as Add-On Therapy of Depression: A Case Series Four depressed patients taking standard antidepressants 2009 Case series n = 4
A longitudinal case series of IM ketamine for patients with severe and enduring eating disorders and comorbid treatment‐resistant depression Patients with enduring eating disorders and treatment-resistant depression 2021 Case series n = 4
Effects of intranasal (S)-ketamine on Veterans with co-morbid treatment-resistant depression and PTSD: A retrospective case series Veterans with co-morbid depression and PTSD 2022 Retrospective case series n = 35
Case report: Intramuscular ketamine or intranasal esketamine as a treatment in four patients with major depressive disorder and comorbid anorexia nervosa Patients with anorexia nervosa and a comorbid depressive disorder treated at a private... 2023 Case report n = 4

Explore topics